BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31413145)

  • 21. The multifunctional Ca2+/calmodulin-dependent kinase II delta (CaMKIIdelta) controls neointima formation after carotid ligation and vascular smooth muscle cell proliferation through cell cycle regulation by p21.
    Li W; Li H; Sanders PN; Mohler PJ; Backs J; Olson EN; Anderson ME; Grumbach IM
    J Biol Chem; 2011 Mar; 286(10):7990-7999. PubMed ID: 21193397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
    Reynisdóttir I; Polyak K; Iavarone A; Massagué J
    Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ClC-3 Chloride Channel Proteins Regulate the Cell Cycle by Up-regulating cyclin D1-CDK4/6 through Suppressing p21/p27 Expression in Nasopharyngeal Carcinoma Cells.
    Ye D; Luo H; Lai Z; Zou L; Zhu L; Mao J; Jacob T; Ye W; Wang L; Chen L
    Sci Rep; 2016 Jul; 6():30276. PubMed ID: 27451945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53.
    Padmakumar VC; Aleem E; Berthet C; Hilton MB; Kaldis P
    Mol Cell Biol; 2009 May; 29(10):2582-93. PubMed ID: 19307310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
    Azmi AS; Philip PA; Aboukameel A; Wang Z; Banerjee S; Zafar SF; Goustin AS; Almhanna K; Yang D; Sarkar FH; Mohammad RM
    Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear factor of activated T cells c1 mediates p21-activated kinase 1 activation in the modulation of chemokine-induced human aortic smooth muscle cell F-actin stress fiber formation, migration, and proliferation and injury-induced vascular wall remodeling.
    Kundumani-Sridharan V; Singh NK; Kumar S; Gadepalli R; Rao GN
    J Biol Chem; 2013 Jul; 288(30):22150-62. PubMed ID: 23737530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E2F1-dependent oncogenic addiction of melanoma cells to MDM2.
    Verhaegen M; Checinska A; Riblett MB; Wang S; Soengas MS
    Oncogene; 2012 Feb; 31(7):828-41. PubMed ID: 21743494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
    Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
    Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
    Skomedal H; Kristensen GB; Lie AK; Holm R
    Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.
    Uzhachenko RV; Bharti V; Ouyang Z; Blevins A; Mont S; Saleh N; Lawrence HA; Shen C; Chen SC; Ayers GD; DeNardo DG; Arteaga C; Richmond A; Vilgelm AE
    Cell Rep; 2021 Apr; 35(1):108944. PubMed ID: 33826903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
    Haricharan S; Punturi N; Singh P; Holloway KR; Anurag M; Schmelz J; Schmidt C; Lei JT; Suman V; Hunt K; Olson JA; Hoog J; Li S; Huang S; Edwards DP; Kavuri SM; Bainbridge MN; Ma CX; Ellis MJ
    Cancer Discov; 2017 Oct; 7(10):1168-1183. PubMed ID: 28801307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JNKs function as CDK4-activating kinases by phosphorylating CDK4 and p21.
    Colleoni B; Paternot S; Pita JM; Bisteau X; Coulonval K; Davis RJ; Raspé E; Roger PP
    Oncogene; 2017 Jul; 36(30):4349-4361. PubMed ID: 28368408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriatic epidermis is associated with upregulation of CDK2 and inhibition of CDK4 activity.
    Henri P; Prevel C; Pellerano M; Lacotte J; Stoebner PE; Morris MC; Meunier L
    Br J Dermatol; 2020 Mar; 182(3):678-689. PubMed ID: 31145809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
    Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
    Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
    Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
    Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
    Giono LE; Manfredi JJ
    Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
    Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
    Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells.
    Lin SY; Lai WW; Chou CC; Kuo HM; Li TM; Chung JG; Yang JH
    Melanoma Res; 2006 Dec; 16(6):509-19. PubMed ID: 17119452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
    PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.